425: Cara Therapeutics Addresses Stockholder Lawsuits and Demands Related to Tvardi Therapeutics Merger

Cara Therapeutics provides supplemental disclosures to its proxy statement/prospectus related to the proposed merger with Tvardi Therapeutics in response to stockholder demands and lawsuits alleging materially false and misleading statements.

Summary

• Cara Therapeutics is updating its proxy statement/prospectus regarding its merger with Tvardi Therapeutics due to stockholder demands and lawsuits.
• Thirteen demands and two lawsuits were filed by Cara stockholders alleging that the Registration Statement contains materially false and misleading statements.
• Cara denies any violations but is providing supplemental disclosures to avoid the burden and expense of litigation.
• The supplemental disclosures include changes to the composition of the combined company's board of directors, details about the legal proceedings, and additional information regarding the selected public companies and IPO analysis used in evaluating the merger.
• The combined company board will consist of seven directors: five designated by Tvardi, one by Cara (Susan Shiff), and one vacancy to be designated later.
• Sujal Shah will serve as Chairman and Imran Alibhai will serve as the Chief Executive Officer of Cara as the combined company.
• All of Cara's current directors other than Ms. Shiff are expected to resign upon the merger's completion.
• Piper Sandler reviewed financial data of selected public companies and IPOs comparable to Tvardi for analysis purposes.
• The lawsuits, filed in the Supreme Court of the State of New York, County of New York, allege omissions or misrepresentations in the Form 424 prospectus.
• Cara urges stockholders to read the proxy statement/prospectus and supplemental disclosures carefully before making any voting or investment decision.

Sentiment

Score: 5

Explanation: The document is primarily a legal and procedural update. While it addresses potential negative issues (lawsuits), it does so in a factual and neutral tone. The sentiment is therefore considered neutral.

Positives

• Cara is proactively addressing stockholder concerns by providing supplemental disclosures.
• The company is aiming to avoid disruption to the merger by addressing the legal challenges.
• The supplemental disclosures provide additional transparency regarding the merger process and board composition.

Negatives

• The lawsuits and demands indicate potential dissatisfaction among some Cara stockholders regarding the merger.
• Legal proceedings could divert management's attention and resources.
• The need for supplemental disclosures suggests potential weaknesses in the initial proxy statement/prospectus.

Risks

• Additional lawsuits and demands may be filed against Cara, Merger Sub, Tvardi, and/or the Cara Board.
• The outcome of the litigation is uncertain, and Cara may not be successful in defending against current or future claims.
• The merger could be delayed or prevented due to lawsuits.
• Securities litigation could divert management's attention and harm the combined company's business.
• Insurance coverage may not be sufficient to cover all costs and damages related to litigation.

Future Outlook

The document contains forward-looking statements regarding the anticipated completion and effects of the proposed Merger, but actual results may differ materially due to various risks and uncertainties.

Management Comments

• Cara and the other named defendants deny that they have violated any laws or breached any duties to stockholders of Cara.
• Cara believes that no supplemental disclosure is required to the proxy statement/prospectus under any applicable law, rule or regulation.
• Cara is providing certain supplemental disclosures solely to eliminate the burden and expense of litigation and to avoid any possible disruption to the Merger.

Industry Context

Mergers and acquisitions in the biopharmaceutical industry often attract scrutiny and potential litigation from stockholders, requiring companies to provide thorough and transparent disclosures.

Comparison to Industry Standards

• The selected public companies analysis includes companies like Pliant Therapeutics, Trevi Therapeutics, and Contineum Therapeutics, which are developing therapies for idiopathic pulmonary fibrosis (IPF).
• The selected IPO analysis includes companies like Upstream Bio, HilleVax, and CinCor Pharma, which completed IPOs since January 1, 2020, with single clinical-stage assets.
• Piper Sandler used these comparables to derive a range of implied equity values for Tvardi, adjusting for net cash.

Management Changes

Legal Proceedings

• Two lawsuits were filed in the Supreme Court of the State of New York, County of New York on March 5 and March 6, 2025 by two purported stockholders of Cara in connection with the Merger.
• Between December 18, 2024 and March 24, 2025, Cara received thirteen demands and three draft complaints from purported stockholders of Cara making substantially similar claims as in the Complaints regarding the disclosures in the proxy statement/prospectus related to the Merger.
• The plaintiffs contended that the Form 424 prospectus filed on February 14, 2025, or the Form 424 Prospectus, omitted or misrepresented material information regarding the Merger, rendering the Form 424 Prospectus false and misleading.

Stakeholder Impact

• Shareholders are urged to read the updated proxy statement/prospectus before making voting decisions.
• The merger will result in a materially reduced ownership and voting interest for Cara and Tvardi equityholders.
• The outcome of the legal proceedings could affect the value stockholders receive in the merger.

Next Steps

• Cara stockholders are urged to submit their proxies for the Cara virtual special meeting.
• Cara will continue to defend against the lawsuits and demands.
• The merger is subject to stockholder approval and the satisfaction (or waiver) of closing conditions.

Key Dates

Keywords

Merger, Cara Therapeutics, Tvardi Therapeutics, Lawsuits, Proxy Statement, Stockholders, Disclosures, Board of Directors, Registration Statement